Condition: EGFR Overexpression · Locally Advanced Solid Tumor · Metastatic Solid Tumor · Sponsor: Yuhan Corporation
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
This description comes directly from the study's public registry record.
Clinical Operation Team 1 · +82-2-828-0150 · clinicaltrials@yuhan.co.kr
Chaebin Lee · +82-2-828-0150 · clinicaltrials@yuhan.co.kr
Always discuss trial participation with your own doctor first.
| Korea University Anam Hospital | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06975410